As daratumumab also acts through antibody-dependent cellular phagocytosis (ADCP) [36], and HDAC6 inhibitors were previously shown to improve antimicrobial human macrophage responses via increased production of reactive oxygen species [37], it is possible that combination therapy can result in enhanced ADCP of MM cells. This evidence concerns the gene HDAC6 and Miyoshi myopathy.